TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
An announcement from Cohen & Steers ( (CNS) ) is now available.
On September 11, 2025, Raja Dakkuri announced his resignation as Executive Vice President and Chief Financial Officer of Cohen & Steers, effective October 17, 2025, to pursue another opportunity. Michael Donohue, the current Senior Vice President and Controller, has been appointed as the Interim Chief Financial Officer. The transition is not due to any disagreements within the company, and a search for a permanent successor is underway. This leadership change is expected to ensure continuity in the company’s financial operations and maintain its strategic direction.
The most recent analyst rating on (CNS) stock is a Buy with a $77.00 price target. To see the full list of analyst forecasts on Cohen & Steers stock, see the CNS Stock Forecast page.
Spark’s Take on CNS Stock
According to Spark, TipRanks’ AI Analyst, CNS is a Outperform.
Cohen & Steers’ overall stock score is driven by strong financial performance and positive earnings call highlights, despite challenges in cash flow management and increased expenses. The technical analysis and valuation suggest a moderate outlook, with no significant corporate events impacting the score.
To see Spark’s full report on CNS stock, click here.
More about Cohen & Steers
Cohen & Steers is a leading global investment manager specializing in real assets and alternative income, including listed and private real estate, preferred securities, infrastructure, resource equities, commodities, as well as multi-strategy solutions. Founded in 1986, the firm is headquartered in New York City, with offices in London, Dublin, Hong Kong, Tokyo, and Singapore.
Average Trading Volume: 233,149
Technical Sentiment Signal: Hold
Current Market Cap: $3.65B
See more data about CNS stock on TipRanks’ Stock Analysis page.